Skip to main content
. 2018 Jun 6;17:526–530. doi: 10.17179/excli2018-1357

Table 2. Review of literature regarding the use, safety, and immune related adverse events (irAEs) by the use of avelumab and other immune checkpoint inhibitors.

Table 2